Assembly Biosciences (ASMB) Stock Price, News & Analysis

Company Overview

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: $10.60 to $11.11
• 50-Day Range: $10.81 to $17.49
• 52-Week Range: $10.56 to $19.93
• Volume: 7,723 shs
• Average Volume: 24,255 shs
• Market Capitalization: $67.44 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $35.00
• Consensus Rating: Moderate Buy

Assembly Biosciences Stock Analysis - MarketRank™

Assembly Biosciences scored higher than 75% of companies evaluated by MarketBeat, and ranked 248th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Assembly Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Assembly Biosciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Assembly Biosciences are expected to decrease in the coming year, from ($6.87) to ($7.64) per share.

Price to Book Value per Share Ratio

Assembly Biosciences has a P/B Ratio of 1.41. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.61% of the float of Assembly Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Assembly Biosciences has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Assembly Biosciences has recently increased by 18.02%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Assembly Biosciences does not currently pay a dividend.

Dividend Growth

Assembly Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.71

Percentage of Shares Shorted

0.61% of the float of Assembly Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Assembly Biosciences has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Assembly Biosciences has recently increased by 18.02%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.25

News Sentiment

Assembly Biosciences has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Assembly Biosciences this week, compared to 9 articles on an average week.

Search Interest

Only 1 people have searched for ASMB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

2 people have added Assembly Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Assembly Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $49,983.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 5.10% of the stock of Assembly Biosciences is held by insiders.

Percentage Held by Institutions

Only 19.92% of the stock of Assembly Biosciences is held by institutions.

ASMB Stock Analysis - Frequently Asked Questions

How have ASMB shares performed this year?

Assembly Biosciences' stock was trading at $15.78 at the start of the year. Since then, ASMB shares have decreased by 32.8% and is now trading at $10.61.
View the best growth stocks for 2025 here.

How were Assembly Biosciences' earnings last quarter?

Assembly Biosciences, Inc. (NASDAQ:ASMB) announced its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($4.92) earnings per share (EPS) for the quarter, topping the consensus estimate of ($6.84) by $1.92. The biopharmaceutical company earned $6.25 million during the quarter. Assembly Biosciences had a negative trailing twelve-month return on equity of 121.46% and a negative net margin of 144.05%.

When did Assembly Biosciences' stock split?

Assembly Biosciences shares reverse split on Monday, February 12th 2024. The 1-12 reverse split was announced on Monday, February 12th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Who are Assembly Biosciences' major shareholders?

Assembly Biosciences' top institutional shareholders include Gilead Sciences Inc. (34.74%), Renaissance Technologies LLC (1.49%), Peapod Lane Capital LLC (0.99%) and B Group Inc. (0.80%). Insiders that own company stock include Alexander Schornstein, John G Mchutchison, Jason A Okazaki, Nicole S White, Michael P Samar, William E Iv Delaney, Michael Houghton, Jeanette M Bjorkquist and Luisa M Stamm.
View institutional ownership trends.

How do I buy shares of Assembly Biosciences?

Shares of ASMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Assembly Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Assembly Biosciences investors own include Waste Connections (WCN), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH), AUO (AUOTY), American Water Works (AWK), The RMR Group (RMR) and iShares Micro-Cap ETF (IWC).

Company Calendar

• Last Earnings: 11/04/2021
• Today: 3/13/2025
• Next Earnings (Estimated): 3/27/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ASMB
• CIK: 1426800
• Web: www.assemblybio.com
• Phone: (833) 509-4583
• Fax: 646-706-5101
• Employees: 100
• Year Founded: 2005

Price Target and Rating

• Average Stock Price Target: $35.00
• High Stock Price Target: $35.00
• Low Stock Price Target: $35.00
• Potential Upside/Downside: +221.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-61,230,000.00
• Net Margins: -144.05%
• Pretax Margin: -142.50%
• Return on Equity: -121.46%
• Return on Assets: -34.56%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.36
• Quick Ratio: 2.36

Sales & Book Value

• Annual Sales: $28.33 million
• Price / Sales: 2.44
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.50 per share
• Price / Book: 1.45

Miscellaneous

• Outstanding Shares: 6,356,000
• Free Float: 6,032,000
• Market Cap: $69.12 million
• Optionable: Optionable
• Beta: 0.62